Teva Pharmaceutical Industries Debt to Equity Ratio 2010-2024 | TEVA
Current and historical debt to equity ratio values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Teva Pharmaceutical Industries debt/equity for the three months ending June 30, 2024 was 2.52.
| Teva Pharmaceutical Industries Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$34.77B |
$6.56B |
5.30 |
| 2024-03-31 |
$35.23B |
$7.54B |
4.67 |
| 2023-12-31 |
$35.35B |
$8.13B |
4.35 |
| 2023-09-30 |
$34.58B |
$7.51B |
4.60 |
| 2023-06-30 |
$35.39B |
$7.71B |
4.59 |
| 2023-03-31 |
$34.84B |
$8.61B |
4.05 |
| 2022-12-31 |
$35.41B |
$8.60B |
4.12 |
| 2022-09-30 |
$34.73B |
$9.52B |
3.65 |
| 2022-06-30 |
$36.10B |
$9.83B |
3.67 |
| 2022-03-31 |
$36.80B |
$10.26B |
3.59 |
| 2021-12-31 |
$36.42B |
$11.24B |
3.24 |
| 2021-09-30 |
$36.40B |
$11.45B |
3.18 |
| 2021-06-30 |
$37.88B |
$11.31B |
3.35 |
| 2021-03-31 |
$38.03B |
$10.98B |
3.47 |
| 2020-12-31 |
$39.58B |
$11.06B |
3.58 |
| 2020-09-30 |
$39.15B |
$10.59B |
3.70 |
| 2020-06-30 |
$40.17B |
$14.82B |
2.71 |
| 2020-03-31 |
$40.74B |
$14.59B |
2.79 |
| 2019-12-31 |
$42.41B |
$15.06B |
2.82 |
| 2019-09-30 |
$42.32B |
$14.93B |
2.84 |
| 2019-06-30 |
$44.17B |
$15.25B |
2.90 |
| 2019-03-31 |
$44.03B |
$15.82B |
2.78 |
| 2018-12-31 |
$44.89B |
$15.79B |
2.84 |
| 2018-09-30 |
$45.93B |
$19.13B |
2.40 |
| 2018-06-30 |
$47.66B |
$19.37B |
2.46 |
| 2018-03-31 |
$49.08B |
$20.10B |
2.44 |
| 2017-12-31 |
$51.87B |
$18.75B |
2.77 |
| 2017-09-30 |
$55.79B |
$30.30B |
1.84 |
| 2017-06-30 |
$56.75B |
$29.61B |
1.92 |
| 2017-03-31 |
$55.53B |
$35.75B |
1.55 |
| 2016-12-31 |
$58.06B |
$34.99B |
1.66 |
| 2016-09-30 |
$61.72B |
$37.03B |
1.67 |
| 2016-06-30 |
$25.90B |
$32.02B |
0.81 |
| 2016-03-31 |
$24.54B |
$30.59B |
0.80 |
| 2015-12-31 |
$24.31B |
$29.93B |
0.81 |
| 2015-09-30 |
$25.73B |
$22.90B |
1.12 |
| 2015-06-30 |
$27.29B |
$23.09B |
1.18 |
| 2015-03-31 |
$24.27B |
$22.68B |
1.07 |
| 2014-12-31 |
$23.07B |
$23.36B |
0.99 |
| 2014-09-30 |
$22.94B |
$23.67B |
0.97 |
| 2014-06-30 |
$23.15B |
$23.59B |
0.98 |
| 2014-03-31 |
$23.86B |
$23.03B |
1.04 |
| 2013-12-31 |
$24.87B |
$22.64B |
1.10 |
| 2013-09-30 |
$25.46B |
$22.39B |
1.14 |
| 2013-06-30 |
$25.89B |
$21.61B |
1.20 |
| 2013-03-31 |
$25.26B |
$22.81B |
1.11 |
| 2012-12-31 |
$27.74B |
$22.87B |
1.21 |
| 2012-09-30 |
$26.51B |
$23.07B |
1.15 |
| 2012-06-30 |
$25.99B |
$22.89B |
1.14 |
| 2012-03-31 |
$27.27B |
$23.20B |
1.18 |
| 2011-12-31 |
$27.80B |
$22.34B |
1.24 |
| 2011-09-30 |
$18.34B |
$22.94B |
0.80 |
| 2011-06-30 |
$16.41B |
$23.75B |
0.69 |
| 2011-03-31 |
$16.12B |
$23.13B |
0.70 |
| 2010-12-31 |
$16.15B |
$22.00B |
0.73 |
| 2010-09-30 |
$17.33B |
$21.71B |
0.80 |
| 2010-06-30 |
$15.82B |
$19.36B |
0.82 |
| 2010-03-31 |
$14.37B |
$19.68B |
0.73 |
| 2009-12-31 |
$14.55B |
$19.26B |
0.76 |
| 2009-09-30 |
$13.99B |
$19.30B |
0.73 |
| 2009-06-30 |
$14.40B |
$17.85B |
0.81 |
| 2009-03-31 |
$16.11B |
$16.14B |
1.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.902B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
